Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00454324 · ClinicalTrials.gov registry record · Phase 2
Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer
A Phase 2 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00454324 is a Phase 2 study that was terminated before completion, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 30 participants.
The verdict
NCT00454324, a Phase 2 study, was terminated before completion, sponsored by UNC Lineberger Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a phase II trial of abraxane and carboplatin in extensive stage small cell lung cancer to examine overall response rate, time to progressive disease, survival time, and assessment of toxicity profile for Carboplatin and Abraxane.
Interventions
- DRUG Carboplatin
- DRUG Abraxane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-04 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00454324
The ClinicalTrials.gov registry entry for NCT00454324 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT00454324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00454324 about?
NCT00454324 is a clinical study titled "Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer". This is a phase II trial of abraxane and carboplatin in extensive stage small cell lung cancer to examine overall response rate, time to progressive disease, survival time, and assessment of toxicity profile for Carboplatin and Abraxane.
What is the current status of trial NCT00454324?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2006-04. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00454324?
The interventions under investigation include: Carboplatin (DRUG), Abraxane (DRUG).
Who is sponsoring clinical trial NCT00454324?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.